

150 Years
Science For A Better Life

Investor Conference Call

Q2 2013 Results

July 31, 2013 / Marijn Dekkers, CEO



Disclaimer

This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management.

Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com.


The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.



Q2 2013 – Highlights

- Life-Sciences with continued operational progress:
 - New pharma product sales significantly exceed expectations, driving pharma growth to 10% organically
 - CropScience grows profitably in overall favorable market environment
- Full-year 2013 new pharma product sales target raised to ~€1.4bn
- Weak performance at MaterialScience in a challenging market environment
- Group sales organically +5%; reported EBIT +74%; adjusted* EBITDA slightly above prior-year level; core EPS +6%
- Full-year 2013 Group outlook maintained even though increasingly ambitious


Q2 2013 – Group Performance: Driven By Life-Sciences



Q2 2013 – Regional Performance: Growth Led By Emerging Economies



In € million, Δ% yoy Fx adjusted




¹ Emerging economies include: Latin America, Asia w/o Japan, Australia, New Zealand, Africa and Middle East incl. Turkey, Eastern Europe
² Others = Japan, Australia, New Zealand, Canada
³ Emerging Asia = Asia w/o Japan, Australia, New Zealand

Q2 2013 – Cash Flow And Net Debt Development




Cash Flow in € million, Net Debt in € billion



Q2 2013 – HealthCare: New Products and Consumer Care Drive Growth



In € million, Δ% yoy, () = Fx & portf. adjusted




*before special items
¹ Prior-year figures restated.

Q2 2013 – CropScience: Continued Good Momentum



In € million, Δ% yoy, () = Fx & portf. adjusted




*before special items
¹ Prior-year figures restated.

Q2 2013 - MaterialScience: Performance

Down Year-Over-Year, Up Quarter-Over-Quarter



In € million, Δ% yoy, () = Fx & portf. adjusted



*before special items

**CAS: Coatings, Adhesives, Specialties

*** IO: Industrial Operations
¹ Prior-year figures restated.


FY 2013 Group Outlook – Maintained, Even Though Increasingly Ambitious After Q2 Results



Sales Δ Fx and portfolio adjusted, EBITDA before special items

	2012 ¹	2013E
Sales	€39.7bn	+4-5% to ~€40-41bn*
adj. EBITDA	€8.3bn	mid-single-digit % increase
Core EPS	€5.30	high-single-digit % increase

*Assuming average Fx rates of H1 2013
 Outlook depends on specific planning assumptions as detailed in the Annual Report
¹ 2012 figures restated



150 Years
Science For A Better Life

Investor Conference Call

Q2 2013 Results

July 31, 2013 / Marijn Dekkers, CEO